» Articles » PMID: 27153324

Systemic Inflammation: Methodological Approaches to Identification of the Common Pathological Process

Overview
Journal PLoS One
Date 2016 May 7
PMID 27153324
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

We defined Systemic inflammation (SI) as a "typical, multi-syndrome, phase-specific pathological process, developing from systemic damage and characterized by the total inflammatory reactivity of endotheliocytes, plasma and blood cell factors, connective tissue and, at the final stage, by microcirculatory disorders in vital organs and tissues." The goal of the work: to determine methodological approaches and particular methodical solutions for the problem of identification of SI as a common pathological process. SI can be defined by the presence in plasma of systemic proinflammatory cell stress products-cytokines and other inflammatory mediators, and also by the complexity of other processes signs. We have developed 2 scales: 1) The Reactivity Level scale (RL)-from 0 to 5 points: 0-normal level; RL-5 confirms systemic nature of inflammatory mediator release, and RL- 2-4 defines different degrees of event probability. 2) The SI scale, considering additional criteria along with RL, addresses more integral criteria of SI: the presence of ≥ 5 points according to the SI scale proves the high probability of SI developing. To calculate the RL scale, concentrations of 4 cytokines (IL-6, IL-8, IL-10, TNF-α) and C-reactive protein in plasma were examined. Additional criteria of the SI scale were the following: D-dimers>500ng/ml, cortisol>1380 or <100nmol/l, troponin I≥0.2ng/ml and/or myoglobin≥800ng/ml. 422 patients were included in the study with different septic (n-207) and aseptic (n-215) pathologies. In 190 cases (of 422) there were signs of SI (lethality 38.4%, n-73). In only 5 of 78 cases, lethality was not confirmed by the presence of SI. SI was registered in 100% of cases with septic shock (n-31). There were not significant differences between AU-ROC of CR, SI scale and SOFA to predict death in patients with sepsis and trauma.

Citing Articles

The Role of Systemic Inflammation in the Pathogenesis of Spontaneous Intracranial Hemorrhage in the Presence or Absence of Effective Cerebral Blood Flow.

Gusev E, Solomatina L, Bochkarev P, Zudova A, Chereshnev V J Clin Med. 2024; 13(15).

PMID: 39124721 PMC: 11313124. DOI: 10.3390/jcm13154454.


Exploring the Pathophysiology of Long COVID: The Central Role of Low-Grade Inflammation and Multisystem Involvement.

Gusev E, Sarapultsev A Int J Mol Sci. 2024; 25(12).

PMID: 38928096 PMC: 11204317. DOI: 10.3390/ijms25126389.


Evaluation of Systemic Inflammation Before and After Standard Anti-tuberculosis Treatment in Patients With Active Pulmonary Tuberculosis and Diabetes Mellitus.

Lopez-Gonzalez J, Martinez-Soto J, Avila-Cervantes C, Mata-Pineda A, Alvarez-Hernandez G, Alvarez-Meza J Cureus. 2024; 16(3):e55391.

PMID: 38562330 PMC: 10984244. DOI: 10.7759/cureus.55391.


Inflammatory Markers and Sleep Architecture in Sleep Bruxism-A Case-Control Study.

Fulek M, Wieckiewicz M, Szymanska-Chabowska A, Gac P, Poreba R, Markiewicz-Gorka I J Clin Med. 2024; 13(3).

PMID: 38337381 PMC: 10856576. DOI: 10.3390/jcm13030687.


Resolvin E1 heals injured cardiomyocytes: Therapeutic implications and H-FABP as a readout for cardiovascular disease & systemic inflammation.

Zheng A, Huang N, Bean D, Rayapaneni S, Deeney J, Sagar M Prostaglandins Leukot Essent Fatty Acids. 2023; 197:102586.

PMID: 37604082 PMC: 11203388. DOI: 10.1016/j.plefa.2023.102586.


References
1.
De Backer D, Donadello K, Taccone F, Ospina-Tascon G, Salgado D, Vincent J . Microcirculatory alterations: potential mechanisms and implications for therapy. Ann Intensive Care. 2011; 1(1):27. PMC: 3224481. DOI: 10.1186/2110-5820-1-27. View

2.
Sakr Y, Dubois M, De Backer D, Creteur J, Vincent J . Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. Crit Care Med. 2004; 32(9):1825-31. DOI: 10.1097/01.ccm.0000138558.16257.3f. View

3.
Pierrakos C, Vincent J . Sepsis biomarkers: a review. Crit Care. 2010; 14(1):R15. PMC: 2875530. DOI: 10.1186/cc8872. View

4.
Bone R, Balk R, Cerra F, Dellinger R, Fein A, Knaus W . Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992; 101(6):1644-55. DOI: 10.1378/chest.101.6.1644. View

5.
Gusev E, Chereshnev V . [Systemic inflammation: theoretical and methodological approaches to description of general pathological process model. Part IV. A dynamics of the process]. Patol Fiziol Eksp Ter. 2015; (4):4-16. View